Search research articles
Contact Us
Filters
Showing results (491-500 of 661) with videos related to
Page
of 67
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 8, 2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China
Shun Lu, Jian Fang, Yan Yu, et al.
Theranostics
|
June 8, 2022
APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases
Run Shi, Xin Wang, Yang Wu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 5, 2026
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort
Xiaorong Dong, Hong Jian, Meijuan Huang, et al.
JTO Clinical and Research Reports
|
October 17, 2022
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With <i>ROS1</i>-Positive Advanced NSCLC
Yi-Long Wu, Shun Lu, James Chih-Hsin Yang, et al.
Cancer Medicine
|
December 24, 2019
Epistatic effect of TLR3 and cGAS-STING-IKKε-TBK1-IFN signaling variants on colorectal cancer risk
Calogerina Catalano, Miguel Inacio da Silva Filho, Christoph Frank, et al.
Environment International
|
December 14, 2025
Association of co-exposure to EDCs in early pregnancy with threatened abortion: The mediation effect of progesterone
Ting-Ting Jiang, Dong-Yang Zhang, Zi-Yi Liu, et al.
Oncology Reports
|
September 30, 2010
Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancer
Jie Zhang, Xiao-Min Niu, Mei-Lin Liao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 9, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study
Shun Lu, Lin Wu, Qiming Wang, et al.
The Lancet. Oncology
|
January 21, 2014
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, et al.
Cell Reports
|
March 4, 2023
Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8<sup>+</sup> T cells with enhanced effector function and anti-tumor response
Cheng-Cheng Yao, Rui-Ming Sun, Yi Yang, et al.
Page
of 67
Search research articles
Search
Showing results (491-500 of 661) with videos related to
Sort By:
Page
of 67
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 8, 2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in China
Shun Lu, Jian Fang, Yan Yu, et al.
Theranostics
|
June 8, 2022
APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases
Run Shi, Xin Wang, Yang Wu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 5, 2026
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort
Xiaorong Dong, Hong Jian, Meijuan Huang, et al.
JTO Clinical and Research Reports
|
October 17, 2022
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With <i>ROS1</i>-Positive Advanced NSCLC
Yi-Long Wu, Shun Lu, James Chih-Hsin Yang, et al.
Cancer Medicine
|
December 24, 2019
Epistatic effect of TLR3 and cGAS-STING-IKKε-TBK1-IFN signaling variants on colorectal cancer risk
Calogerina Catalano, Miguel Inacio da Silva Filho, Christoph Frank, et al.
Environment International
|
December 14, 2025
Association of co-exposure to EDCs in early pregnancy with threatened abortion: The mediation effect of progesterone
Ting-Ting Jiang, Dong-Yang Zhang, Zi-Yi Liu, et al.
Oncology Reports
|
September 30, 2010
Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancer
Jie Zhang, Xiao-Min Niu, Mei-Lin Liao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 9, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study
Shun Lu, Lin Wu, Qiming Wang, et al.
The Lancet. Oncology
|
January 21, 2014
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, et al.
Cell Reports
|
March 4, 2023
Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8<sup>+</sup> T cells with enhanced effector function and anti-tumor response
Cheng-Cheng Yao, Rui-Ming Sun, Yi Yang, et al.
Page
of 67